A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

NCT06764875 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

840

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Rilvegostomig
DRUG: Trastuzumab deruxtecan
DRUG: Trastuzumab
DRUG: Pembrolizumab
DRUG: 5-fluorouracil
DRUG: Capecitabine
DRUG: Cisplatin
DRUG: Oxaliplatin

Sponsor

AstraZeneca